Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder
Information source: Case Comprehensive Cancer Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Intervention: ascorbic acid (Dietary Supplement); arsenic trioxide (Drug); dexamethasone (Drug); thalidomide (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Case Comprehensive Cancer Center Official(s) and/or principal investigator(s): Mikkael A. Sekeres, MD, MS, Study Chair, Affiliation: The Cleveland Clinic
Summary
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and dexamethasone, work in
different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Sometimes when chemotherapy is given, it does not stop the
growth of cancer cells. The cancer is said to be resistant to chemotherapy. Giving ascorbic
acid may reduce drug resistance and allow the cancer cells to be killed. Thalidomide may
stop the growth of cancer cells by blocking blood flow to the cancer. Giving arsenic
trioxide together with ascorbic acid, dexamethasone, and thalidomide may kill more cancer
cells.
PURPOSE: This phase II trial is studying how well giving arsenic trioxide together with
ascorbic acid, dexamethasone, and thalidomide works in treating patients with chronic
idiopathic myelofibrosis or myelodysplastic or myeloproliferative disorders.
Clinical Details
Official title: A Phase II Trial of Combination Therapy With Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients With Chronic Idiopathic Myelofibrosis or Overlap Myelodysplastic/Myeloproliferative Disorders
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Response rate at 6 months
Secondary outcome: Bone marrow response at 6 monthsSpleen size at 12 weeks Quality of life
Detailed description:
OBJECTIVES:
Primary
- Evaluate the efficacy (in terms of response rate) of arsenic trioxide, ascorbic acid,
dexamethasone, and thalidomide in patients with chronic idiopathic myelofibrosis or
myelodysplastic/myeloproliferative disorders.
Secondary
- Determine the rate of disease progression or progression to acute leukemia in patients
treated with this regimen.
- Assess improvement in bone marrow pathology (including degree of fibrosis, percentage
of blasts, and resolution of cytogenetic abnormalities) in patients treated with this
regimen.
- Determine time to response in patients treated with this regimen.
- Determine the reduction of spleen size in patients treated with this regimen.
- Measure clinical responses and quality of life in subgroups treated with this regimen.
- Determine the safety of this regimen in these patients.
OUTLINE: This is an open-label, multicenter study.
Patients receive arsenic trioxide IV over 1-2 hours for 5 days and oral ascorbic acid once
daily for 5 days during week 1. Patients then receive arsenic trioxide and ascorbic acid
twice a week in weeks 2-12. Patients also receive oral dexamethasone once daily for 5 days
in weeks 1, 5, 9, and 12 and oral thalidomide once or twice daily in weeks 1-12. Courses
repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline and after every course.
After completion of study treatment, patients are followed periodically.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
DISEASE CHARACTERISTICS:
- Chronic idiopathic myelofibrosis or myelodysplastic/myeloproliferative disorders
(MDS/MPD), including the following subtypes:
- Chronic idiopathic myelofibrosis (with extramedullary hematopoiesis)
- Chronic myelomonocytic leukemia (CMML)
- Atypical chronic myeloid leukemia
- MDS/MPD disease, unclassifiable
- MDS with ≥ 2+ fibrosis present in the bone marrow
- Patients with MPD must be negative by fluorescent in situ hybridization
(FISH) for the BCR/ABL fusion gene
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy of at least 3 months
- Platelet count > 10,000/mm³
- Bilirubin ≤ 2. 5 times upper limit of normal (ULN)
- SGOT and SGPT ≤ 2. 5 times ULN
- Creatinine ≤ 1. 5 times ULN
- Potassium ≥ 4. 0 mEq/dL (supplemental electrolytes allowed)
- Magnesium > 1. 8 mg/dL (supplemental electrolytes allowed)
- Absolute QTc interval < 460 msec
- Patients who have a QT > 460 after electrolyte repletion and discontinuation of
other unessential QT-prolonging drugs will be excluded
- Negative pregnancy test
- Women of childbearing potential must use medically acceptable birth control (two
methods of birth control or at least one highly active method and one additional
effective method), starting 4 weeks prior to starting thalidomide, all through
thalidomide therapy, and for 4 weeks after discontinuing thalidomide
- Male patients with reproductive potential must use a latex condom every time they
have sex with a woman from the time that they start taking thalidomide, all through
thalidomide therapy, and for 4 weeks after discontinuing thalidomide
- No sperm or blood donation during study treatment
- Must be willing and able to comply with the FDA-mandated System for Thalidomide
Educational Prescribing and Safety (S. T.E. P.S™) program
- No other serious medical condition, laboratory abnormality, or psychiatric illness
that, in the view of the treating physician, would place the patient at an
unacceptable risk if he or she were to participate in the study or would prevent that
person from giving informed consent
- No preexisting neurotoxicity/neuropathy ≥ grade 2
- Not pregnant or nursing
- No cardiac conduction defects
- No unstable angina
- No myocardial infarction within the past 6 months
- No congestive heart failure of any cause
- No New York Heart Association class II or greater
- No other significant underlying cardiac dysfunction
- No prior malignancy in the 3 years before treatment in this study (other than
curatively treated carcinoma in situ of the cervix or nonmelanoma skin cancer)
- No sulfa allergy that would interfere with administration of trimethoprim
sulfamethoxazole prophylaxis
- Patients with sulfa allergies who could instead receive pentamidine prophylaxis
also will be excluded
- Patients with sulfa allergies who can instead receive atovaquone may be included
PRIOR CONCURRENT THERAPY:
- At least 4 weeks since prior investigational or approved therapy for this disease
- No growth factors within 1 week of study enrollment
- No other concurrent cytotoxic drugs or other investigational agents
Locations and Contacts
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio 44106-5065, United States
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio 44195, United States
Additional Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Starting date: October 2005
Last updated: September 26, 2012
|